Clinical Research Directory

Inclusion Criteria: 1. Children with a clinical diagnosis of infantile hemangioma. 2. Complete pretreatment clinical documentation is available, including clinical photographs and/or ultrasound findings. 3. The child has received oral propranolol for at least 6 months. 4. The infantile hemangioma meets the predefined criteria for propranolol discontinuation, defined as complete or near-complete clinical regression, no obvious residual blood flow on ultrasound, and stable maximal regression for 3 months. 5. Written informed consent is provided by a parent or legal guardian. 6. The parent or legal guardian is able and willing to complete the scheduled follow-up assessments. Exclusion Criteria: 1. Airway or hepatic infantile hemangiomas, or other high-risk lesions for which rebound growth could rapidly compromise life or vital organ function. 2. Use of propranolol for arrhythmia, hypertension, or another cardiovascular indication. 3. A history of rebound growth after prior discontinuation of propranolol. 4. Laser therapy, sclerotherapy, surgery, systemic corticosteroids, or other systemic treatment within 3 months before randomization. 5. Severe cardiac, respiratory, hepatic, renal, metabolic, or other systemic disease that may affect participant safety or study assessment. 6. Inability to complete standardized photography, ultrasound assessment, or scheduled follow-up.